Journal Article
. 2018 Sep; 6(1):83.
doi: 10.1186/s40425-018-0393-z.

Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases

Christine A Garcia 1 Alex El-Ali 2 Tanya J Rath 2 Lydia C Contis 3 Vikram Gorantla 1 Jan Drappatz 1 Diwakar Davar 4 
Affiliations
  • PMID: 30170622
  •     43 References
  •     19 citations

Abstract

Background: PD-1 and CTLA-4 inhibitors are associated with several adverse events including a spectrum of immune-related adverse effects (irAEs). Neurologic irAEs are uncommon occurrences with varied presentations. We describe two separate cases of ipilimumab associated meningoencephalomyelitis and demyelinating polyneuropathy with unusual presentations.

Case Presentation: Two melanoma patients were treated with ipilimumab in the adjuvant setting. The first patient developed a meningoencephalitis following 3 doses of ipilimumab. MRI imaging of the brain confirmed leptomeningeal enhancement although cerebrospinal fluid (CSF) analyses were negative for malignant cells consistent with meningoencephalomyelitis. Although she initially improved following treatment with steroids and intravenous immunoglobulin, she subsequently relapsed. She was successfully treated with infliximab and made a complete neurological recovery. A second patient developed progressive lower extremity weakness following two doses of ipilimumab. MRI imaging of the spine confirmed diffuse nerve root enhancement consistent with acute inflammatory demyelinating polyneuropathy (AIDP). He was treated with high dose steroids with resolution of neurological symptoms. Both patients remain disease free.

Conclusions: Neurological irAEs are uncommon adverse events in the context of CTLA-4 and/or PD-1 inhibitor therapy. Care must be taken to distinguish these from leptomeningeal disease. Early recognition of neurological irAEs is critical for the initiation of specific anti-inflammatory agents to prevent and potentially reverse neurological sequelae.

Keywords: Autoimmune; CTLA-4; Cancer; Guillain Barre syndrome; Immune-related adverse events; Immunotherapy; Infliximab; Ipilimumab; Melanoma; Meningoencephalomyelitis; Neurotoxicity; TNF-α.

Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.
Al-Ola Abdallah, Aline Herlopian, +6 authors, Laura Hutchins.
J Oncol Pharm Pract, 2015 Feb 26; 22(3). PMID: 25712627
Review.
Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.
Shintaro Iwama, Alessandra De Remigis, +3 authors, Patrizio Caturegli.
Sci Transl Med, 2014 Apr 04; 6(230). PMID: 24695685
Highly Cited.
Human Leukocyte Antigen DQB1 (HLA-DQB1) Polymorphisms and the Risk for Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis.
Peng-Peng Jin, Li-Li Sun, +10 authors, Shuang-Xing Hou.
PLoS One, 2015 Jul 24; 10(7). PMID: 26204120    Free PMC article.
Systematic Review.
Severe meningo-radiculo-neuritis associated with ipilimumab.
Flavie Bompaire, Christine Mateus, +8 authors, Damien Ricard.
Invest New Drugs, 2012 Jan 11; 30(6). PMID: 22231551
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Kimberly E Beck, Joseph A Blansfield, +12 authors, James C Yang.
J Clin Oncol, 2006 May 20; 24(15). PMID: 16710025    Free PMC article.
Highly Cited.
Neurological immune-related adverse events of ipilimumab.
Ilja Bot, Christian U Blank, Willem Boogerd, Dieta Brandsma.
Pract Neurol, 2013 Mar 15; 13(4). PMID: 23487828
Peripheral neuropathy associated with ipilimumab: a report of 2 cases.
Iyavut Thaipisuttikul, Paul Chapman, Edward K Avila.
J Immunother, 2015 Feb 07; 38(2). PMID: 25658617    Free PMC article.
Ipilimumab-induced encephalopathy with a reversible splenial lesion.
Robert M Conry, Joseph C Sullivan, Louis B Nabors.
Cancer Immunol Res, 2015 Apr 30; 3(6). PMID: 25922203
Infliximab for IPILIMUMAB-Related Colitis-Letter.
Edurne Arriola, Matthew Wheater, +2 authors, Christian Ottensmeier.
Clin Cancer Res, 2015 Dec 17; 21(24). PMID: 26672088
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Emanuela Romano, Monika Kusio-Kobialka, +7 authors, Daniel E Speiser.
Proc Natl Acad Sci U S A, 2015 Apr 29; 112(19). PMID: 25918390    Free PMC article.
Highly Cited.
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Mark J Selby, John J Engelhardt, +11 authors, Alan J Korman.
PLoS One, 2016 Sep 10; 11(9). PMID: 27610613    Free PMC article.
Highly Cited.
Ipilimumab treatment associated with myasthenic crises and unfavorable disease course.
Eda Derle, Sibel Benli.
Neurol Sci, 2018 Jun 28; 39(10). PMID: 29948466
Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.
S Wilgenhof, B Neyns.
Ann Oncol, 2011 Mar 02; 22(4). PMID: 21357649
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
M F Krummel, J P Allison.
J Exp Med, 1995 Aug 01; 182(2). PMID: 7543139    Free PMC article.
Highly Cited.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A Postow, Jason Chesney, +18 authors, F Stephen Hodi.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891304    Free PMC article.
Highly Cited.
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Dirk Schadendorf, F Stephen Hodi, +7 authors, Jedd D Wolchok.
J Clin Oncol, 2015 Feb 11; 33(17). PMID: 25667295    Free PMC article.
Highly Cited.
Toxicity management of immunotherapy for patients with metastatic melanoma.
Helena Linardou, Helen Gogas.
Ann Transl Med, 2016 Aug 27; 4(14). PMID: 27563659    Free PMC article.
Review.
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.
Krista Dubin, Margaret K Callahan, +9 authors, Jedd D Wolchok.
Nat Commun, 2016 Feb 03; 7. PMID: 26837003    Free PMC article.
Highly Cited.
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Julie R Brahmer, Christina Lacchetti, +27 authors, National Comprehensive Cancer Network.
J Clin Oncol, 2018 Feb 15; 36(17). PMID: 29442540    Free PMC article.
Highly Cited.
Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barré syndrome.
L Schirmer, V Worthington, +12 authors, Bernhard Hemmer.
J Neurol, 2016 Aug 04; 263(10). PMID: 27485170
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Acute cerebellitis after administration of nivolumab and ipilimumab for small cell lung cancer.
Tatsuhiko Naito, Masao Osaki, +2 authors, Yoshikazu Uesaka.
Neurol Sci, 2018 Jun 28; 39(10). PMID: 29948463
Lambrolizumab induced central nervous system (CNS) toxicity.
Jacob J Mandel, Adriana Olar, Kenneth D Aldape, Ivo W Tremont-Lukats.
J Neurol Sci, 2014 Jul 02; 344(1-2). PMID: 24980937    Free PMC article.
The Mayo Clinic Experience With the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab.
Michael W Ruff, Michelle L Mauermann.
Neurologist, 2018 May 04; 23(3). PMID: 29722744
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
F Stephen Hodi, Marcus Butler, +17 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2008 Feb 22; 105(8). PMID: 18287062    Free PMC article.
Highly Cited.
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.
L Spain, G Walls, +7 authors, J Larkin.
Ann Oncol, 2017 Apr 21; 28(2). PMID: 28426103
Highly Cited. Review.
Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.
R L Johnston, J Lutzky, A Chodhry, J S Barkin.
Dig Dis Sci, 2008 Dec 24; 54(11). PMID: 19104936
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.
N Chaput, P Lepage, +15 authors, F Carbonnel.
Ann Oncol, 2017 Apr 04; 28(6). PMID: 28368458
Highly Cited.
Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.
Bing Liao, Sheetal Shroff, Carlos Kamiya-Matsuoka, Sudhakar Tummala.
Neuro Oncol, 2014 Feb 01; 16(4). PMID: 24482447    Free PMC article.
Highly Cited.
Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma.
Vera Montes, Sandra Sousa, +2 authors, Cátia Carmona.
Front Neurol, 2018 Apr 19; 9. PMID: 29666602    Free PMC article.
Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma.
Douglas B Johnson, Vita Saranga-Perry, +7 authors, Jeffrey A Sosman.
J Clin Oncol, 2014 Apr 30; 33(33). PMID: 24778401    Free PMC article.
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
Jeffrey Weber.
Oncologist, 2007 Aug 04; 12(7). PMID: 17673617
Review.
Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
Jia-Hung Chen, Kang-Yun Lee, Chaur-Jong Hu, Chen-Chih Chung.
Medicine (Baltimore), 2018 Feb 03; 96(50). PMID: 29390370    Free PMC article.
Review.
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Alexander M M Eggermont, Vanna Chiarion-Sileni, +24 authors, Alessandro Testori.
N Engl J Med, 2016 Oct 09; 375(19). PMID: 27717298    Free PMC article.
Highly Cited.
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
Douglas B Johnson, Monica V Estrada, +18 authors, Justin M Balko.
Nat Commun, 2016 Jan 30; 7. PMID: 26822383    Free PMC article.
Highly Cited.
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.
Claire F Friedman, Tracy A Proverbs-Singh, Michael A Postow.
JAMA Oncol, 2016 Jul 02; 2(10). PMID: 27367787
Highly Cited. Review.
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
James Larkin, Bartosz Chmielowski, +9 authors, David A Reardon.
Oncologist, 2017 May 13; 22(6). PMID: 28495807    Free PMC article.
Highly Cited.
A clinical approach to diagnosis of autoimmune encephalitis.
Francesc Graus, Maarten J Titulaer, +25 authors, Josep Dalmau.
Lancet Neurol, 2016 Feb 26; 15(4). PMID: 26906964    Free PMC article.
Highly Cited. Review.
Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.
Tanya J Williams, David R Benavides, +6 authors, Ellen M Mowry.
JAMA Neurol, 2016 Jun 09; 73(8). PMID: 27271951
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Controlling of glutamate release by neuregulin3 via inhibiting the assembly of the SNARE complex.
Ya-Nan Wang, Dwight Figueiredo, +12 authors, Lin Mei.
Proc Natl Acad Sci U S A, 2018 Feb 22; 115(10). PMID: 29463705    Free PMC article.
Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
Catherine A Gao, Urs M Weber, Aldo J Peixoto, Sarah A Weiss.
J Immunother Cancer, 2019 Oct 19; 7(1). PMID: 31623673    Free PMC article.
Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature.
Nicholas Gravbrot, Katalin Scherer, Srinath Sundararajan.
Case Rep Oncol Med, 2019 Dec 31; 2019. PMID: 31885974    Free PMC article.
Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma.
James Lopez, Naveen Yarlagadda, +2 authors, Appalanaidu Sasapu.
Proc (Bayl Univ Med Cent), 2020 Feb 18; 33(1). PMID: 32063772    Free PMC article.
Decreasing Microtubule Actin Cross-Linking Factor 1 Inhibits Melanoma Metastasis by Decreasing Epithelial to Mesenchymal Transition.
Xiaoying Wang, Xiao Jian, +2 authors, Fengshu Zhao.
Cancer Manag Res, 2020 Feb 27; 12. PMID: 32099463    Free PMC article.
Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation.
Victoria A Chang, Daniel R Simpson, Gregory A Daniels, David E Piccioni.
J Immunother Cancer, 2018 Dec 24; 6(1). PMID: 30577851    Free PMC article.
A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab.
Daniel J Olson, Padma Rajagopal, +3 authors, Thomas F Gajewski.
J Immunother Cancer, 2020 Mar 15; 8(1). PMID: 32169870    Free PMC article.
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.
Douglas B Johnson, Ali Manouchehri, +6 authors, Joe-Elie Salem.
J Immunother Cancer, 2019 May 24; 7(1). PMID: 31118078    Free PMC article.
Highly Cited.
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance.
Marcus A Couey, R Bryan Bell, +5 authors, Rom S Leidner.
J Immunother Cancer, 2019 Jul 05; 7(1). PMID: 31269983    Free PMC article.
Review.
Advances in cancer immunotherapy 2019 - latest trends.
Stephan Kruger, Matthias Ilmer, +12 authors, Michael von Bergwelt-Baildon.
J Exp Clin Cancer Res, 2019 Jun 21; 38(1). PMID: 31217020    Free PMC article.
Highly Cited. Review.
How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation.
Roshini S Abraham.
Hematology Am Soc Hematol Educ Program, 2020 Dec 05; 2020(1). PMID: 33275711    Free PMC article.
Review.
Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature.
Marcos C B Oliveira, Marcelo H de Brito, Mateus M Simabukuro.
Front Neurol, 2020 Dec 29; 11. PMID: 33362680    Free PMC article.
Review.
Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department.
Sai-Ching Jim Yeung, Aiham Qdaisat, +18 authors, Kumar Alagappan.
J Am Coll Emerg Physicians Open, 2021 Jan 05; 1(6). PMID: 33392573    Free PMC article.
Neurotoxicities associated with immune checkpoint inhibitor therapy.
Sophie L Duong, Frank J Barbiero, Richard J Nowak, Joachim M Baehring.
J Neurooncol, 2021 Jan 18; 152(2). PMID: 33454891
Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review.
Laure Thouvenin, Timothée Olivier, +2 authors, Alex Friedlaender.
Ther Adv Drug Saf, 2021 Apr 16; 12. PMID: 33854755    Free PMC article.
Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab.
Salma Charabi, Lotte Engell-Noerregaard, Anna Christine Nilsson, Christian Stenör.
Front Neurol, 2021 May 18; 12. PMID: 33995251    Free PMC article.
A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment.
Tomoyo Oguri, Shinji Sasada, +9 authors, Morio Nakamura.
J Investig Med High Impact Case Rep, 2021 Aug 05; 9. PMID: 34344201    Free PMC article.
Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases.
Yan Li, Xiuchun Zhang, Chuansheng Zhao.
Biomed Res Int, 2021 Aug 31; 2021. PMID: 34458371    Free PMC article.
Systematic Review.
Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development.
Ke Cheng, Yuqing Wang, +3 authors, Jiyan Liu.
Clin Med Insights Oncol, 2021 Dec 07; 15. PMID: 34866959    Free PMC article.
Review.
Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review.
Simon Nannini, Larysa Koshenkova, +3 authors, Roland Schott.
J Neurooncol, 2022 Apr 14; 157(3). PMID: 35416575
Systematic Review.